Recently targeted kinases and their inhibitors-the path to clinical trials

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Protein kinases are crucial targets for cancer therapy, with 28 inhibitors approved.
• Current clinical trials predominantly focus on existing kinase inhibitors or well-validated targets.
• Novel kinase targets are underutilized in clinical trials despite extensive research validation.

Purpose of the Study:

• To analyze the target validation history of first-in-class kinase inhibitors.
• To identify first-in-class kinase inhibitors entering Phase I trials in the last five years.
• To examine research approaches used for validating these novel kinase targets.

Main Methods:

• Retrospective analysis of clinical trial data and scientific literature.
• Identification of kinase inhibitors entering Phase I clinical trials.
• Review of target validation strategies and timelines.

Main Results:

• A significant delay exists between initial disease association and the development of kinase inhibitors.
• Limited clinical trials are investigating novel kinase targets, despite substantial public domain validation.
• Analysis focused on inhibitors entering Phase I trials within the last five years.

Conclusions:

• There is a translational gap in developing novel kinase inhibitors for cancer treatment.
• Future research should focus on accelerating the clinical development of inhibitors targeting novel kinase pathways.
• Optimizing target validation and early-phase clinical trial initiation is critical for advancing cancer therapy.